Intellective Biologics

Executive Summary

Intellective Biologics is a leading China-based contract development and manufacturing organization (CDMO) specializing in biologics and antibody-drug conjugates (ADCs). Founded in 2018 and headquartered in Suzhou, the company provides end-to-end services from preclinical development through commercial manufacturing for monoclonal antibodies, ADCs, and Fc fusion proteins. With over 500 employees, Intellective focuses on oncology and immunology therapeutics, leveraging its integrated platform to serve a growing pipeline of clients. As a private, platform-stage company, it has established itself as a key player in the rapidly expanding biologics outsourcing market, benefiting from the global shift towards targeted therapies and the increasing demand for complex biologics manufacturing. Intellective's strategic focus on ADC development positions it well for the anticipated surge in ADC-based therapies. The company is investing in capacity expansion and technological innovation to meet the needs of both domestic and international clients. While the CDMO market is competitive, Intellective's integrated service platform and cost advantages in China provide a competitive edge. Recent investments in production facilities and quality systems have enhanced its ability to support late-phase and commercial projects. As the biologics outsourcing market grows, Intellective Biologics is poised to capture additional market share, particularly in the high-growth ADC segment.

Upcoming Catalysts (preview)

• Q3 2026Expansion of ADC manufacturing capacity70% success
• Q4 2026Strategic partnership with a top 20 pharma company50% success
• Q2 2026Regulatory approval for commercial production of a client's biologic60% success